Bambusa Therapeutics to Present Phase 1 Data on Novel Atopic Dermatitis Antibody at ISDS 2025

Bambusa Therapeutics Inc has shared an update. The company announced that it will present Phase 1 clinical data for BBT001, a novel bispecific IL-4Rα/IL-31 antibody, at the 6th Inflammatory Skin Disease Summit (ISDS 2025) in New York City. The poster, titled “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody: Phase 1 Single-Ascending-Dose Study Results in Healthy Volunteers” (Paper #360), will be presented on November 13, 2025, during an evening poster session at The New York Academy of Medicine. The company also highlighted its bispecific antibody platform and its focus on atopic dermatitis.

For investors, this update signals continued progress in Bambusa Therapeutics’ clinical development pipeline, with BBT001 having advanced through a Phase 1 single-ascending-dose study in healthy volunteers. While specific efficacy or safety outcomes are not disclosed in the post, the selection of these data for presentation at a specialized inflammatory skin disease summit suggests scientific relevance and provides an opportunity for peer validation and feedback from key opinion leaders. Successful early-stage safety and pharmacokinetic/pharmacodynamic data are prerequisites for advancing to patient trials, which, if favorable, could ultimately support a differentiated biologic candidate in the competitive atopic dermatitis market. The company’s visibility at ISDS 2025 may enhance its profile among potential partners, licensors, or investors, potentially supporting future funding or collaboration discussions, although near-term revenue impact remains contingent on subsequent trial phases and regulatory milestones.